Lilly reported 48% second-quarter revenue growth and 33% non-GAAP EPS growth, which included acquisition charges. Management raised the midpoints of its 2026 guidance to $86 billion in revenue and $36 per share in non-GAAP EPS. Shares rose 5% on Aug. 5.
Lilly's strong leadership in weight-loss drugs should drive industry-leading growth, given its approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.
The risks to success for Kisunla remain high because of bottlenecks in patient diagnosis, required scans and monitoring, and competition, particularly from Eisai/Biogen (Leqembi) and Roche (pipeline drug trontinemab).
|
Metric
|
LLY
|
MRK
|
NVO
|
|---|---|---|---|
Price/Earnings (Normalized) | 36.50 | 46.83 | 11.56 |
Price/Book Value | 30.24 | 8.85 | 6.10 |
Price/Sales | 12.94 | 5.60 | 4.03 |
Price/Cash Flow | 31.34 | 16.83 | 9.65 |
|
Metric
|
LLY
|
MRK
|
NVO
|
|---|---|---|---|
Quick Ratio | 0.68 | 0.71 | 0.64 |
Current Ratio | 1.35 | 1.32 | 0.87 |
Interest Coverage | — | 4.28 | — |
|
Metric
|
LLY
|
MRK
|
NVO
|
|---|---|---|---|
Return on Assets (Normalized) | 24.05% | 6.27% | 21.31% |
Return on Equity (Normalized) | 105.62% | 16.68% | 59.99% |
Return on Invested Capital (Normalized) | 39.55% | 9.82% | 34.79% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Johnson & Johnson
JNJ
| LOCK|&<&#s^g | LOCK|?@f | $663B | |||
| AbbVie Inc
ABBV
| LOCK|#??>&g | LOCK|h% | $453B | |||
| Merck & Co Inc
MRK
| LOCK|%FqGSS | LOCK|S?t | $371B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|#!b%@>tl | LOCK|D<# | $353B | |||
| Novartis AG ADR
NVS
| LOCK|$>#@BDF | LOCK|nr | $305B | |||
| AstraZeneca PLC
AZN
| LOCK|Ff<#?wff | LOCK|#k | $252B | |||
| Amgen Inc
AMGN
| LOCK|@^V^@m%! | LOCK|&n$ | $236B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|H^&>#pb | LOCK|FC | $206B | |||
| Gilead Sciences Inc
GILD
| LOCK|%vy<M#r | LOCK|#^F | $187B |
United States